AZN - Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry | Benzinga
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AstraZeneca (NASDAQ:AZN) against its key competitors in the Pharmaceuticals industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
AstraZeneca Background
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | |||||||
| 35.07 | |||||||
| 5.52 | |||||||
| 4.60 | |||||||
| 3.68% | |||||||
| $3.33 | |||||||
| $9.4 | |||||||
| 4.64% | |||||||
| Eli Lilly and Co | |||||||
| 103.33 | |||||||
| 48.26 | |||||||
| 16.07 | |||||||
| -0.52% | |||||||
| $0.96 | |||||||
| $7.64 | |||||||
| 36.84% | |||||||
| Novo Nordisk A/S | |||||||
| 41.62 | |||||||
| 33.36 | |||||||
| 14.62 | |||||||
| 24.5% | |||||||
| $32.76 | |||||||
| $49.02 | |||||||
| 28.89% | |||||||
| Johnson & Johnson | |||||||
| 29.17 | |||||||
| 5.25 | |||||||
| 4.12 | |||||||
| 35.56% | |||||||
| $7.24 | |||||||
| $14.74 | |||||||
| 6.78% | |||||||
| Merck & Co Inc | |||||||
| 59.83 | |||||||
| 6.62 | |||||||
| 4.63 | |||||||
| 11.87% | |||||||
| $6.95 | |||||||
| $11.7 | |||||||
| 6.71% | |||||||
| Novartis AG | |||||||
| 25.58 | |||||||
| 5.32 | |||||||
| 3.85 | |||||||
| 3.91% | |||||||
| $4.88 | |||||||
| $8.97 | |||||||
| 12.14% | |||||||
| Pfizer Inc | |||||||
| 15.52 | |||||||
| 1.65 | |||||||
| 2.37 | |||||||
| -2.43% | |||||||
| $-1.1 | |||||||
| $3.96 | |||||||
| -41.55% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 13.27 | |||||||
| 3.67 | |||||||
| 2.44 | |||||||
| 6.32% | |||||||
| $4.85 | |||||||
| $8.46 | |||||||
| -2.25% | |||||||
| Zoetis Inc | |||||||
| 39.71 | |||||||
| 17.63 | |||||||
| 10.81 | |||||||
| 12.28% | |||||||
| $0.9 | |||||||
| $1.51 | |||||||
| 7.44% | |||||||
| GSK PLC | |||||||
| 9.85 | |||||||
| 4.57 | |||||||
| 2.02 | |||||||
| 11.34% | |||||||
| $2.55 | |||||||
| $5.88 | |||||||
| 4.06% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 32.90 | |||||||
| 0.89 | |||||||
| 1.51 | |||||||
| -0.69% | |||||||
| $202.28 | |||||||
| $699.51 | |||||||
| 4.07% | |||||||
| Viatris Inc | |||||||
| 7.05 | |||||||
| 0.61 | |||||||
| 0.83 | |||||||
| 1.59% | |||||||
| $1.22 | |||||||
| $1.69 | |||||||
| -3.34% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 18.32 | |||||||
| 3.68 | |||||||
| 3.49 | |||||||
| 5.94% | |||||||
| $23.28 | |||||||
| $40.37 | |||||||
| 9.11% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 146.08 | |||||||
| 2.19 | |||||||
| 2.23 | |||||||
| 4.19% | |||||||
| $0.33 | |||||||
| $0.87 | |||||||
| 3.35% | |||||||
| Corcept Therapeutics Inc | |||||||
| 40.95 | |||||||
| 7.31 | |||||||
| 8.24 | |||||||
| 7.06% | |||||||
| $0.03 | |||||||
| $0.12 | |||||||
| 21.5% | |||||||
| Amphastar Pharmaceuticals Inc | |||||||
| 23.80 | |||||||
| 4.90 | |||||||
| 5.34 | |||||||
| 8.31% | |||||||
| $0.09 | |||||||
| $0.11 | |||||||
| 50.3% | |||||||
| Average | |||||||
| 40.47 | |||||||
| 9.73 | |||||||
| 5.5 | |||||||
| 8.62% | |||||||
| $19.15 | |||||||
| $56.97 | |||||||
| 9.6% |